FLT3 (FMS-related Tyrosine Kinase 3) Mutation Analysis, Blood
FLT3 also known as flk2 (fetal liver kinase 2) is a class III receptor tyrosine kinase that belongs to the same family as FMS, KIT, and the two genes encoding PDGFR α and β. The FLT3 plays a vital role in hematopoietic cell differentiation and hematopoietic cell survival and proliferation, as well as in the development of dendritic cells and natural killer lymphocytes. Activation of FLT3 in response to mutation leads to both direct and indirect autophosphorylation/phosphorylation of various proteins, resulting in alterations in gene expression. FLT3 mutations are the most frequent mutations associated with acute myeloid leukemia (AML).
There are two types of flt3 gene mutation: internal tandem duplication (ITD) that occurs between exons 14 and 15 (previously known as exons 11 and 12) and the gene mutation that involves a single base pair substitution (missense point mutation) in codon 835 of exon 20 (previously known as exon 17).
Flt3 gene mutations of the ITD type have been detected in approx 25% of AMLs. D835 mutations occur in 5–10% of AML cases. Both types of mutation constitutively activate FLT3 which results in increase cell proliferation. These mutations have been associated with poor prognosis and higher relapse rates. FLT3 is also overexpressed in a smaller subset of T-acute lymphocytic leukemia (ALL) and chronic myeloid leukemia (CML) in blast crisis. Both ITD and D835 types of flt3 gene mutations are easily detected by polymerase chain reaction (PCR) and RFLP followed by capillary electrophoresis.
- Testing is helpful at initial diagnosis of AML, ALL, and myeloproliferative/ myelodysplastic syndrome (MDS)
- As an aid in differentiation and classification of AML
- Prognostic grouping of AML into high and low risk
- May help determine treatment options including specific tyrosine kinase inhibitor therapy
- Treatment monitoring and disease management
- Aids detection of recurrent disease
- Over expressed in most B lineage and acute myeloid leukemias.
- Over expressed in a smaller subset of T-cell acute Lymphocytic leukemia.
- FLT3 over expression may also be present in CML in blast crisis.
- Patients with a high mutant-to-wild type ratio have a significantly shorter disease-free survival, increased relapse risk, and decreased overall survival.
- Positive results are reported identifying a specific missense point mutation or, in the case of internal tandem duplication (ITD) mutation, results are expressed quantitatively as % abnormal.
Negative for mutation analyzed (Mutation not detected)
Whole blood / bone marrow in heparin, EDTA (lavender top tube), or ACD (blue top tube).
Stability
- Ambient: 3-5 days
- Refrigerated: 5-7 days
- Frozen: 30 days
- J Mol Diagn. 2003 May;5(2):96-102. [PMID: 12707374]
- Leuk Lymphoma. 2002 Aug;43(8):1541-7. [PMID: 12400596]
- Blood. 2007 Aug 15;110(4):1262-70. Epub 2007 Apr 24. [PMID: 17456725]
- Leukemia. 2012 Jul 13. doi: 10.1038/leu.2012.191. [PMID: 22858906]
- Blood. 2006 Dec 1;108(12):3654-61. [PMID: 16912228]
- Am J Clin Pathol. 2006 Oct;126(4):530-3. [PMID: 16938665]